Profilaksis prapendedahan (Malay Wikipedia)

Analysis of information sources in references of the Wikipedia article "Profilaksis prapendedahan" in Malay language version.

refsWebsite

Global rank Malay rank

20nih.gov

4^th place

14^th place

11doi.org

2^nd place

8^th place

6wikipedia.org

low place

5who.int

195^th place

103^rd place

4cdc.gov

218^th place

90^th place

3web.archive.org

1^st place

2fda.gov

447^th place

467^th place

2poz.com

low place

2sfaf.org

low place

2aidshealth.org

low place

1hiv.gov

low place

1prepwatch.org

low place

1latimes.com

22^nd place

280^th place

1harvard.edu

18^th place

46^th place

1aidsmap.com

low place

8,178^th place

1healio.com

low place

2,758^th place

1gilead.com

low place

1tvnz.co.nz

2,766^th place

low place

1afao.org.au

low place

afao.org.au

"PrEP". Australian Federation of AIDS Organisations. Dicapai pada 2020-07-31.

aidshealth.org

Kenslea, Ged (11 April 2019). "41 HIV and PrEP Patients File California Personal Injury Lawsuit Over Gilead's TDF-Based Drugs". AIDS Healthcare Foundation (AHF). Dicapai pada 9 Disember 2019.
"AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs". AIDS Healthcare Foundation (AHF). 16 Julai 2019. Dicapai pada 10 Disember 2019.

aidsmap.com

"PrEP does not raise lipids or alter body fat, safety study finds". Dicapai pada 2018-02-16.

cdc.gov

US Public Health Service. "Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014" (PDF). Centers for Disease Control and Prevention (CDC). Diarkibkan daripada yang asal (PDF) pada 11 April 2018. Dicapai pada 15 Disember 2017.
"Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV". Centers for Disease Control and Prevention (CDC). 2019-11-12. Diarkibkan daripada yang asal pada 10 Disember 2019. Dicapai pada 9 Disember 2019.
"Pre-Exposure Prophylaxis (PrEP) | HIV Risk and Prevention | HIV/AIDS | CDC". www.cdc.gov. 2020-06-04. Dicapai pada 2020-07-30.
"Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update Clinical Practice Guideline" (PDF). Centers for Disease Control and Prevention.

doi.org

"HIV Preexposure Prophylaxis: A Review". JAMA. 319 (12): 1261–1268. March 2018. doi:10.1001/jama.2018.1917. PMID 29584848.
"Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. Januari 2001. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. Unknown parameter |displayauthors= ignored (bantuan)
"Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. June 2019. doi:10.1001/jama.2019.2591. PMID 31184746. Unknown parameter |displayauthors= ignored (bantuan)
"Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. December 2017. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
"Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions". Drugs. 79 (12): 1263–1276. August 2019. doi:10.1007/s40265-019-01143-8. PMID 31309457.
"Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. December 2016. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714. Unknown parameter |displayauthors= ignored (bantuan)
"HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. April 2020. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523. Unknown parameter |displayauthors= ignored (bantuan)
"Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. April 2017. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
"Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. March 2010. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. 2014-03-13. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530. Unknown parameter |displayauthors= ignored (bantuan)
"Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. August 2018. doi:10.1016/S2352-3018(18)30072-9. PMID 29885813. Unknown parameter |displayauthors= ignored (bantuan)

fda.gov

"FDA approves the second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic" (Siaran akhbar). 3 Oktober 2019. Diarkibkan daripada yang asal pada 10 Oktober 2019. Dicapai pada 10 Oktober 2019. Rencana ini mengandungi teks dari suatu penerbitan yang kini berada dalam domain awam:
"FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention". U.S. Food and Drug Administration. 20 Disember 2021. Dicapai pada 20 April 2022.

gilead.com

Gilead. "U.S. Food and Drug Administration Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV". Gilead. Dicapai pada 15 Disember 2017.

harvard.edu

ui.adsabs.harvard.edu

"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. 2014-03-13. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530. Unknown parameter |displayauthors= ignored (bantuan)

healio.com

"Truvada as HIV PrEP not associated with net fat increase". www.healio.com. Dicapai pada 2018-02-16.

hiv.gov

"Pre-Exposure Prophylaxis". HIV.gov. 2019-12-03. Dicapai pada 2020-08-03.

latimes.com

Petersen, Melody (29 May 2016). "A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner". Los Angeles Times. Dicapai pada 9 Disember 2019.

nih.gov

pubmed.ncbi.nlm.nih.gov

"HIV Preexposure Prophylaxis: A Review". JAMA. 319 (12): 1261–1268. March 2018. doi:10.1001/jama.2018.1917. PMID 29584848.
"Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. Januari 2001. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. Unknown parameter |displayauthors= ignored (bantuan)
"Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. June 2019. doi:10.1001/jama.2019.2591. PMID 31184746. Unknown parameter |displayauthors= ignored (bantuan)
"Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. December 2017. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
"Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions". Drugs. 79 (12): 1263–1276. August 2019. doi:10.1007/s40265-019-01143-8. PMID 31309457.
"HIV preexposure prophylaxis: new data and potential use". Topics in Antiviral Medicine. 19 (5): 181–5. December 2011. PMC 6148898. PMID 22298887.
"Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. December 2016. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714. Unknown parameter |displayauthors= ignored (bantuan)
"HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. April 2020. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523. Unknown parameter |displayauthors= ignored (bantuan)
"Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. April 2017. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
"Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. March 2010. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. 2014-03-13. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530. Unknown parameter |displayauthors= ignored (bantuan)
"Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. August 2018. doi:10.1016/S2352-3018(18)30072-9. PMID 29885813. Unknown parameter |displayauthors= ignored (bantuan)

ncbi.nlm.nih.gov

"Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. December 2017. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
"HIV preexposure prophylaxis: new data and potential use". Topics in Antiviral Medicine. 19 (5): 181–5. December 2011. PMC 6148898. PMID 22298887.
"Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. December 2016. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714. Unknown parameter |displayauthors= ignored (bantuan)
"HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. April 2020. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523. Unknown parameter |displayauthors= ignored (bantuan)
"Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. April 2017. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
"Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. March 2010. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. 2014-03-13. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530. Unknown parameter |displayauthors= ignored (bantuan)

dailymed.nlm.nih.gov

"Truvada- emtricitabine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Dicapai pada 9 Disember 2019.

poz.com

Ryan, Benjamin (16 Februari 2017). "PrEP Fails in a Third Man, But This Time HIV Drug Resistance Is Not to Blame". Poz. Dicapai pada 15 Disember 2017.
"Changes to Your Face and Body (Lipodystrophy & Wasting)". Poz. Dicapai pada 2018-02-16.

prepwatch.org

"National Policies and Guidelines for PrEP". PrEP Watch. Dicapai pada 5 Disember 2017.

sfaf.org

"New research at CROI 2016: How PrEP changes kidney function". San Francisco AIDS Foundation. 2016-03-08. Dicapai pada 2020-08-03.
"Resource: Side-by-side comparison: Truvada and Descovy for PrEP". San Francisco AIDS Foundation. Dicapai pada 2020-08-03.

tvnz.co.nz

"HIV prevention drug Truvada to be publicly funded in New Zealand". TVNZ. Dicapai pada 7 Februari 2018.

web.archive.org

US Public Health Service. "Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014" (PDF). Centers for Disease Control and Prevention (CDC). Diarkibkan daripada yang asal (PDF) pada 11 April 2018. Dicapai pada 15 Disember 2017.
"Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV". Centers for Disease Control and Prevention (CDC). 2019-11-12. Diarkibkan daripada yang asal pada 10 Disember 2019. Dicapai pada 9 Disember 2019.
"FDA approves the second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic" (Siaran akhbar). 3 Oktober 2019. Diarkibkan daripada yang asal pada 10 Oktober 2019. Dicapai pada 10 Oktober 2019. Rencana ini mengandungi teks dari suatu penerbitan yang kini berada dalam domain awam:

who.int

apps.who.int

"Preventing HIV During Pregnancy And Breastfeeding in the Context of PrEP". WHO Technical Brief: 16. 2017.
"Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects" (PDF). Pertubuhan Kesihatan Sedunia (WHO). July 2012.
"Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2014" (PDF). Pertubuhan Kesihatan Sedunia (WHO). July 2014.
"WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)" (PDF). Pertubuhan Kesihatan Sedunia (WHO). November 2015. Dicapai pada 18 Disember 2015.

who.int

"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection". World Health Organization.

wikipedia.org

en.wikipedia.org

"Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. Januari 2001. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. Unknown parameter |displayauthors= ignored (bantuan)
"Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. June 2019. doi:10.1001/jama.2019.2591. PMID 31184746. Unknown parameter |displayauthors= ignored (bantuan)
"Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. December 2016. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714. Unknown parameter |displayauthors= ignored (bantuan)
"HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. April 2020. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523. Unknown parameter |displayauthors= ignored (bantuan)
"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. 2014-03-13. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530. Unknown parameter |displayauthors= ignored (bantuan)
"Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. August 2018. doi:10.1016/S2352-3018(18)30072-9. PMID 29885813. Unknown parameter |displayauthors= ignored (bantuan)